Daratumumab biosimilar - Biocad
Alternative Names: BCD-264Latest Information Update: 11 Mar 2024
At a glance
- Originator Biocad
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Multiple myeloma
Most Recent Events
- 21 Dec 2023 Phase-III clinical trials in Multiple myeloma (Second-line therapy or greater) in Russia (IV) (NCT06296121)
- 17 May 2023 Phase-I clinical trials in Unspecified (In volunteers) in Russia (IV) (NCT05974969)